119744-42-2

Basic information

• Product Name: 4-Cyanophenethyl Methanesulfonate
• Synonyms: 4-Cyanophenethyl Methanesulfonate;4-[2-[(methylsulfonyl)oxy]ethyl]Benzonitrile
• CAS NO: 119744-42-2
• Molecular Formula: C₁₀H₁₁NO₃S
• Molecular Weight: 225.26424
• Mol File: 119744-42-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-Cyanophenethyl Methanesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyanophenethyl Methanesulfonate(119744-42-2)
• EPA Substance Registry System: 4-Cyanophenethyl Methanesulfonate(119744-42-2)

Safety Data

• Hazardous Substances Data: 119744-42-2(Hazardous Substances Data)

Upstream product

• 69395-13-7 4-(2-hydroxyethyl)benzonitrile 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 335619-10-8 4-{2-[7-(3,3-dimethyl-2-oxobutyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}benzonitrile 
• 218138-99-9 4-[2-(4-formylphenoxy)ethyl]benzonitrile 
• 1097209-59-0 C₂₇H₂₇ClFN₃O₂ 
• 1097636-19-5 C₂₇H₂₈ClN₃O₂ 
• 714568-47-5 4-(2-azidoethyl)benzonitrile 
• 119745-54-9 [(S)-1-{(R)-1-[({[2-(4-Cyano-phenyl)-ethyl]-ethyl-carbamoyl}-methyl)-carbamoyl]-4-guanidino-butylcarbamoyl}-2-(4-hydroxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 119744-97-7 ({[2-(4-Cyano-phenyl)-ethyl]-ethyl-carbamoyl}-methyl)-carbamic acid tert-butyl ester 

Relevant articles and documents

3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2H-isoquinolin-1-one compounds that, inter alia, inhibit PARP (e.g., PARP1, TNKS1, TNKS2, etc.

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I): Chemical formula should be inserted here as it appears on the abstract in paper form. or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1 receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.

NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS

2-Quinoxalinone derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

KETOPIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS

Ketopiperazine derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Oxabispidine compounds useful in the treatment of cardiac arrhyythmias

There is provided compounds of formula I, wherein R1, R2, R3, R4, R41to R46, A, B and G have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives

Novel thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives, process for their manufacture, pharmaceutical preparations containing them and the use of the compounds in conditions associated with insulin resistance.

Bispidine antiarrhythmic compounds

There is provided a compound of formula I, wherein R1, R2, R9, R10, R11, R12, X, A and B have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.

Piperazine, piperidine and tetrahydropyridine derivative of indol-3-alkyl as 5-HT1D-α agonists

Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms, optionally substituted in any position by a hydroxy group; T represents nitrogen or CH; U represents nitrogen or C--R2 ; V represents oxygen, sulphur or N--R3 ; --F--G-- represents --CH2--N--, --CH2--CH-- or --CH=C--; R1 represents C3-6 alkenyl, C3-6 alkynyl, aryl(C1-6)alkyl or heteroaryl(C1-6)alkyl, any of which groups may be optionally substituted; and R2 and R3 independently represent hydrogen or C1-6 alkyl are selective agonists of 5-HT1D receptors, being potent agonists of the human 5-HT1Dalpha receptor subtype, while possessing at least a 10-fold selective affinity for the 5-HT1Dalpha receptor subtype, relative to the 5-HT1Dbeta subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.